Current and historical daily PE Ratio for Acarix AB (
) from 2016 to Jun 14 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Acarix AB stock (OSTO:ACARIX) PE ratio as of Jun 14 2024 is 0.
More Details
Acarix AB (OSTO:ACARIX) PE Ratio (TTM) Chart
Acarix AB (OSTO:ACARIX) PE Ratio (TTM) Historical Data
View and export this data going back to 2016. Start your Free Trial
Total 1288
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| Acarix AB PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-14 | At Loss | 2024-04-09 | At Loss |
| 2024-06-13 | At Loss | 2024-04-08 | At Loss |
| 2024-06-12 | At Loss | 2024-04-05 | At Loss |
| 2024-06-11 | At Loss | 2024-04-04 | At Loss |
| 2024-06-10 | At Loss | 2024-04-03 | At Loss |
| 2024-06-07 | At Loss | 2024-04-02 | At Loss |
| 2024-06-05 | At Loss | 2024-03-28 | At Loss |
| 2024-06-04 | At Loss | 2024-03-27 | At Loss |
| 2024-06-03 | At Loss | 2024-03-26 | At Loss |
| 2024-05-31 | At Loss | 2024-03-25 | At Loss |
| 2024-05-30 | At Loss | 2024-03-22 | At Loss |
| 2024-05-29 | At Loss | 2024-03-21 | At Loss |
| 2024-05-28 | At Loss | 2024-03-20 | At Loss |
| 2024-05-27 | At Loss | 2024-03-19 | At Loss |
| 2024-05-24 | At Loss | 2024-03-18 | At Loss |
| 2024-05-23 | At Loss | 2024-03-15 | At Loss |
| 2024-05-22 | At Loss | 2024-03-14 | At Loss |
| 2024-05-21 | At Loss | 2024-03-13 | At Loss |
| 2024-05-20 | At Loss | 2024-03-12 | At Loss |
| 2024-05-17 | At Loss | 2024-03-11 | At Loss |
| 2024-05-16 | At Loss | 2024-03-08 | At Loss |
| 2024-05-15 | At Loss | 2024-03-07 | At Loss |
| 2024-05-14 | At Loss | 2024-03-06 | At Loss |
| 2024-05-13 | At Loss | 2024-03-05 | At Loss |
| 2024-05-10 | At Loss | 2024-03-04 | At Loss |
| 2024-05-08 | At Loss | 2024-03-01 | At Loss |
| 2024-05-07 | At Loss | 2024-02-29 | At Loss |
| 2024-05-06 | At Loss | 2024-02-28 | At Loss |
| 2024-05-03 | At Loss | 2024-02-27 | At Loss |
| 2024-05-02 | At Loss | 2024-02-26 | At Loss |
| 2024-04-30 | At Loss | 2024-02-23 | At Loss |
| 2024-04-29 | At Loss | 2024-02-22 | At Loss |
| 2024-04-26 | At Loss | 2024-02-21 | At Loss |
| 2024-04-25 | At Loss | 2024-02-20 | At Loss |
| 2024-04-24 | At Loss | 2024-02-19 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
Acarix AB (OSTO:ACARIX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Acarix AB
ISIN : SE0009268717
Compare
Compare
Traded in other countries / regions
ACARIX.SwedenACIXF.USA7AC.Germany IPO Date
2016-12-19Description
Acarix AB is a Swedish medical technology company that develops innovative solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor System uses advanced acoustics and AI technology to non-invasively rule out CAD in less than 10 minutes, with at least 96 percent certainty.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers